Denali Therapeutics Inc. (DNLI) Stock Price, Financials & Summary

Price chart

Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16

Key dataOct 16, 2026

Open$18.18

From 52W high−35.28%

Volume2.28M

Market cap$2.81B

P/E (TTM)—

P/S (TTM)781.1x

Div yield—

Key dataOct 16, 2026

Open

$18.18

From 52W high

−35.28%

Volume

2.28M

Market cap

$2.81B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.3x

P/E (TTM)

—

RSI (14)

29.8

MomentumView details →

1D Return

−3.98%

YTD Return

+6.06%

SummaryUpdated Jun 1, 2026

Denali Therapeutics Inc. (NASDAQ:DNLI) is a biopharmaceutical company founded in 2013 and headquartered in South San Francisco, California. Originally incorporated as SPR Pharma Inc., the company changed its name to Denali Therapeutics in March 2015 and went public in December 2017. Denali focuses exclusively on discovering and developing therapeutic candidates for neurodegenerative diseases, a challenging area of medicine where few effective treatments currently exist. The company operates as a clinical-stage biotech firm with multiple drug candidates in various phases of development, targeting conditions such as Parkinson's disease, ALS (amyotrophic lateral sclerosis), Huntington's disease, and other neurological disorders.

Ask drillr about Denali Therapeutics Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−4.3x

EV/Sales

591.6x

P/S (TTM)

781.1x

P/B (TTM)

3.4x

ProfitabilityView details →

Gross Margin

−61.04%

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−61.24%

ROA (TTM)

−44.17%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−1.43%

FCF YoY

−18.89%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−15.56%

EBITDA YoY

+0.15%

MomentumView details →

1D Return

−3.98%

YTD Return

+6.06%

1Y Return

+5.10%

RSI (14)

29.8

vs 50D SMA

−19.84%

vs 200D SMA

−17.21%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

8.37x

Quick Ratio

8.32x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.68

EPS Surprise

−32.54%

Beats (12Q)

5/12

Next Q EPS Est

−$0.63

Avg Surprise (4Q)

−3.44%

Rev Surprise

67.29%

Financials snapshotView financials →

Revenue (TTM)

3.60M

Net Income (TTM)

−511.45M

Op. CF (TTM)

−434.04M

Next earningsNov 5, 2026 →

Latest newsMore news →

Denali Therapeutics reported Q2 2026 financial results, including AVLAYAH net product revenue of $3.6 million and a net loss of $127.6 million.72d ago

Similar companies

Arcus Biosciences, Inc.RCUS Celcuity Inc.CELC Soleno Therapeutics, Inc.SLNO Genor Biopharma Holdings Limited06998.HK Viva Biotech Holdings01873.HK Medtide Inc.03880.HK Find similar companies →

Latest newsMore news →

Denali Therapeutics launched AVLAYAH, an FDA-approved rare-disease therapy, and reported Q2 2026 revenue of $3.6 million, with projected Q3 revenue tripling due to accelerating patient uptake and payer coverage progress.64d ago Denali Therapeutics reported Q2 2026 financial results, including AVLAYAH net product revenue of $3.6 million and a net loss of $127.6 million.72d ago Denali Therapeutics sold a Priority Review Voucher for gross proceeds of $195 million in July 2026.72d ago